(Health-NewsWire.Net, September 29, 2017 ) Anorexia is defined as the loss of the desire to eat. Progressive wasting is common in many types of cancer and is one of the most important factors leading to early death in cancer patients. Advanced cancer undergo a wasting syndrome associated with cancer anorexia/cachexia and asthenia. Cancer anorexia or cachexia often is associated with weakness, fatigue, and a poor quality of life. This symptom of anorexia not only affects the patient but also frequently has an impact on family members, as the patient is no longer able to participate fully in eating as a social activity.
Report Highlights
Publisher's Pharmaceutical and Healthcare latest pipeline guide Cancer Anorexia-Cachexia Syndrome-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Cancer Anorexia-Cachexia Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Get Sample Copy of Report@ http://www.reportsweb.com/inquiry&RW00011060434/sample
The Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cancer Anorexia-Cachexia Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 1, 1, 9 and 3 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively.
Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Inquiry for Buying@ http://www.reportsweb.com/inquiry&RW00011060434/buying
List of Tables Number of Products under Development for Cancer Anorexia-Cachexia Syndrome, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Cancer Anorexia-Cachexia Syndrome-Pipeline by Abreos Biosciences Inc, H2 2017 Cancer Anorexia-Cachexia Syndrome-Pipeline by Acacia Pharma Ltd, H2 2017 Cancer Anorexia-Cachexia Syndrome-Pipeline by Aeterna Zentaris Inc, H2 2017 Cancer Anorexia-Cachexia Syndrome-Pipeline by Incyte Corp, H2 2017 Cancer Anorexia-Cachexia Syndrome-Pipeline by Lakewood-Amedex Inc, H2 2017 Cancer Anorexia-Cachexia Syndrome-Pipeline by Novartis AG, H2 2017 Cancer Anorexia-Cachexia Syndrome-Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2017 Cancer Anorexia-Cachexia Syndrome-Pipeline by RaQualia Pharma Inc, H2 2017 Cancer Anorexia-Cachexia Syndrome-Pipeline by Viking Therapeutics Inc, H2 2017 Cancer Anorexia-Cachexia Syndrome-Pipeline by Zeria Pharmaceutical Co Ltd, H2 2017 Cancer Anorexia-Cachexia Syndrome-Dormant Projects, H2 2017 Cancer Anorexia-Cachexia Syndrome-Dormant Projects, H2 2017 (Contd..1), H2 2017 Cancer Anorexia-Cachexia Syndrome-Discontinued Products, H2 2017
Buy This Report@ http://www.reportsweb.com/buy&RW00011060434/buy/2000
List of Figures Number of Products under Development for Cancer Anorexia-Cachexia Syndrome, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Number of Products by Top 10 Targets, H2 2017 Number of Products by Stage and Top 10 Targets, H2 2017 Number of Products by Top 10 Mechanism of Actions, H2 2017 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 Number of Products by Routes of Administration, H2 2017 Number of Products by Stage and Routes of Administration, H2 2017 Number of Products by Molecule Types, H2 2017 Number of Products by Stage and Molecule Types, H2 2017
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|